Two Chinese alliances for Amerigen as it pursues branded generics opportunities
This article was originally published in Scrip
The privately held US/Chinese firm Amerigen Pharmaceuticals has joined the ranks of companies building up their branded generics businesses in China through two alliances it hopes will extend its reach in this growing sector.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.